Athenex (NASDAQ:ATNX) has strategically expanded its presence in Europe and Latin America to grow its R&D capacity.
These initiatives will enhance Company’s capacity to conduct global clinical studies and support its regional marketing decision process.
Athenex’s oncology-focused pipeline currently has nine clinical candidates, including two drug candidates in Phase III development.
The Company is currently conducting clinical studies in UK to continue expanding its R&D capabilities in the region.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.